Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 16,400 shares, a decline of 34.4% from the December 15th total of 25,000 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.

Analysts Set New Price Targets

Separately, HC Wainwright raised shares of Basilea Pharmaceutica to a “strong-buy” rating in a research report on Monday, September 23rd.

Basilea Pharmaceutica Stock Performance

BPMUF stock remained flat at $52.83 on Thursday. Basilea Pharmaceutica has a fifty-two week low of $38.60 and a fifty-two week high of $52.83. The firm has a 50 day moving average of $52.83 and a 200 day moving average of $51.08.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.